Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 1144 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

Table of Contents
Year : 2011  |  Volume : 15  |  Issue : 8  |  Page : 395-401

Renin-angiotensin system activity in vitamin D deficient, obese individuals with hypertension: An urban Indian study

1 Department of Endocrinology, Medwin Hospitals, Hyderabad, Andhra Pradesh, India
2 Department of Anesthesia, Central Security hospital, Riyadh, Saudi Arabia
3 Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Berhampur, India
4 Department of Medicine, MKCG Medical College, Berhampur, India
5 Department of Cardiology, JIPMER, Puducherry, India
6 Department of Anatomy, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India

Date of Web Publication1-Nov-2011

Correspondence Address:
Sunil Kumar Kota
Department of Endocrinology, Medwin Hospitals, Chiragh Ali Lane, Nampally, Hyderabad - 500 001, Andhra Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2230-8210.86985

Rights and Permissions

Background: Elevated renin-angiotensin-aldosterone system (RAAS) activity is an important mechanism in the development of hypertension. Both obesity and 25-hydroxy vitamin D [25(OH)D] deficiency have been associated with hypertension and augmented renin-angiotensin system (RAS) activity. We tried to test the hypothesis that vitamin D deficiency and obesity are associated with increased RAS activity in Indian patients with hypertension. Materials and Methods: Fifty newly detected hypertensive patients were screened. Patients with secondary hypertension, chronic kidney disease, or coronary artery disease were excluded. Patients underwent measurement of vitamin D and plasma renin and plasma aldosterone concentrations. They were divided into three groups according to their baseline body mass index (BMI; normal <25 kg/m 2 , overweight 25-29.9 kg/m 2 and obese ≥30 kg/m 2 ) and 25(OH)D levels (deficient <20 ng/ml, insufficient 20-29 ng/ml and optimal ≥30 ng/ml). Results: A total of 50 (male:female = 32:18) patients were included, with a mean age of 49.5 ± 7.8 years, mean BMI of 28.3 ± 3.4 kg/m 2 and a mean 25(OH)D concentration of 18.5 ± 6.4 ng/ml. Mean systolic blood pressure (SBP) was 162.4 ± 20.2 mm Hg and mean diastolic blood pressure (DBP) was 100.2 ± 11.2 mm Hg. All the three blood pressure parameters [SBP, DBP and mean arterial pressure (MAP)] were significantly higher among individuals with lower 25(OH)D levels. The P values for trends in SBP, DBP and MAP were 0.009, 0.01 and 0.007, respectively. Though all the three blood pressure parameters (SBP, DBP and MAP) were higher among individuals with higher BMIs, they were not achieving statistical significance. Increasing trends in PRA and PAC were noticed with lower 25(OH)D and higher BMI levels. Conclusion: Vitamin D deficiency and obesity are associated with stimulation of RAAS activity. Vitamin D supplementation along with weight loss may be studied as a therapeutic strategy to reduce tissue RAS activity in individualswith Vitamin D deficiency and obesity.

Keywords: Hypertension, obesity, renin-angiotensin-aldosterone system, vitamin D

How to cite this article:
Kota SK, Kota SK, Jammula S, Meher LK, Panda S, Tripathy PR, Modi KD. Renin-angiotensin system activity in vitamin D deficient, obese individuals with hypertension: An urban Indian study. Indian J Endocr Metab 2011;15, Suppl S4:395-401

How to cite this URL:
Kota SK, Kota SK, Jammula S, Meher LK, Panda S, Tripathy PR, Modi KD. Renin-angiotensin system activity in vitamin D deficient, obese individuals with hypertension: An urban Indian study. Indian J Endocr Metab [serial online] 2011 [cited 2020 Sep 29];15, Suppl S4:395-401. Available from: http://www.ijem.in/text.asp?2011/15/8/395/86985

   Introduction Top

Obesity is a state of relative vitamin D deficiency [1] and excess tissue renin angiotensin aldosterone system (RAAS) activity. [2] There is a local adipose tissue RAAS that produces all the components of RAAS and is distinctly regulated from the circulating RAAS. [3] Vitamin D is an inhibitor of renin expression in animals via its interaction with vitamin D receptor (VDR). [4]

Li et al. showed that VDR knockout mice displayed a phenotype of high plasma renin activity (PRA) and hypertension that was ameliorated with renin-angiotensin system (RAS) antagonism. [5] Inhibiting the production of active 1,25-dihydroxyvitamin D [1,25(OH)2D] by inactivating the 1α-hydroxylase enzyme also resulted in high PRA, which was reduced with the administration of 1,25(OH)2D. [6] In contrast, overexpression of the VDR in juxtaglomerular cells of mice suppressed renin expression independently of parathyroid hormone and calcium. [7] These findings have been consolidated by implicating vitamin D as an inhibitor of renin gene expression via its interaction with the VDR. [8]

Cross-sectional human studies have also associated vitamin D deficiency with augmented RAAS activity, particularly in obesity. [9] They have also found that vitamin D metabolites have been inversely associated with circulating renin. [10] Vitamin D deficiency and excess activity of RAAS are associated with cardiovascular disease. [11] In the present study, we tried to evaluate the association between RAAS activity with vitamin D levels and obesity. To ourknowledge, this is the first such study on Indian patients.

   Materials and Methods Top

Subjects who were newly diagnosed to have hypertension defined by a seated blood pressure >140/90 mm Hg at two occasions were screened. All patients underwent a screening history and physical, laboratory examinations. Patients with chronic kidney disease, coronary artery disease, heart failure or known causes of secondary hypertension were excluded.

The study was approved by the hospital ethical committee and all the participants signed informed consent forms after being thoroughly explained about the study.

Measurement of serum 25(OH)D was performed in all patients. All subjects had PRA and plasma aldosterone (PAC) measured from the morning supine blood samples. Subjects were categorized by their vitamin D status on the basis of their 25(OH)D levels as follows: group 1 - optimal (≥30 ng/ml); group 2 - insufficient (20.0-29.9 ng/ml) and group 3 - deficient (<20.0 ng/ml). [12] Similarly, the participants were categorized on the basis of their body mass index (BMI) (normal <25 kg/m 2 , overweight: 25-29.9 kg/m 2 and obese ≥30 kg/ m 2 ).

Statistical analysis

Summary data were expressed as mean ± standard deviation and comparison between groups was done by nonparametric Mann-Whitney U test. Relationship between vitamin D levels and RAAS parameters in the overall study population was analyzed by Pearson correlation analysis. One-way analysis of variance (ANOVA) was used to compare means between BMI categories. P values were two-tailed and values <0.05 were considered significant. All the statistical analyses were performed using online GraphPad QuickCalc software.

   Results Top

A total of 50 (male:female = 32:18) patients were included in the study group. The study population's mean age was 49.5 ± 7.8 years (range: 25-68 years). They were overweight with a BMI of 28.3 ± 3.4 kg/m 2 (range: 21.2-36.4) and had a mean 25(OH)D concentration of 18.5 ± 6.4 ng/ml (range: 7.3-33.5 ng/ml). Mean systolic blood pressure (SBP) was 162.4 ± 20.2 mm Hg and mean diastolic blood pressure (DBP) was 100.2 ± 11.2 mm Hg.

Vitamin D and blood pressure and renin angiotensin aldosterone system parameters

[Table 1] depicts the blood pressure and RAAS parameters in the participants as per their 25(OH)D levels. The graph in [Figure 1] demonstrates the mean blood pressure values as per the vitamin D levels. All the three blood pressure parameters [SBP, DBP and mean arterial pressure (MAP)] were significantly higher among individuals with lower 25(OH)D levels. The P values for trends in SBP, DBP and MAP were 0.009, 0.01 and 0.007, respectively. Increasing trends in PRA and PAC were noticed as vitamin D levels were decreasing. Though PRA values were significantly higher in group 2 (insufficient) versus group 3 (optimal) (P = 0.004), they did not significantly differ according to the vitamin D status in group 2 (insufficient) versus group 1 (deficient) (P = 0.09). However, PAC levels maintained significant trend across the three groups. Patients under group 1 were obese, whereas patients in groups 2 and 3 were overweight. Though BMI was higher among individuals with lower 25(OH)D levels, the difference was statistically not significant.
Figure 1: Mean arterial pressure in patients as per their serum vitamin D levels

Click here to view
Table 1: Blood pressure and renin angiotensin aldosterone system parameters in subjects as per their vitamin D levels (*P < 0.05)

Click here to view

Body mass index and blood pressure and renin angiotensin aldosterone system parameters

BMI-wise distribution of blood pressure and RAAS parameters is given in [Table 2]. The graph in [Figure 2] demonstrates the mean blood pressure values as per the BMI. Though all the three blood pressure parameters (SBP, DBP and MAP) were higher among individuals with higher BMIs, they did not achieve statistical significance. The P values for trends in SBP, DBP and MAP were 0.06, 0.09 and 0.07, respectively. Increasing trends in PRA and PAC were noticed as the BMI was increasing. Though PRA and PAC values were significantly higher in overweight versus lean subjects (P = 0.001), they did not significantly differ according to the BMI status in obese versus overweight subjects (P = 0.1). Overweight patients had significantly lower levels of 25(OH)D than normal BMI subjects. The 25(OH)D levels did not vary significantly vary between overweight and obese subjects.
Figure 2: Mean arterial pressure in patients as per their body mass index

Click here to view
Table 2: Blood pressure and renin angiotensin aldosterone system parameters in subjects as per their body mass index (*P < 0.05)

Click here to view

   Discussion Top

The relationship between vitamin D, RAAS and obesity is complex and intertwined. Although animal models strongly suggest that vitamin D suppresses the RAAS, there are limited human data supporting this hypothesis. Indian data in this respect are not available s far. We found that lower 25(OH)D levels and higher BMI values were associated with higher plasma renin and aldosterone concentration in Indian subjects with hypertension.

Observational studies strongly support an inverse association between plasma 25(OH)D levels and blood pressure and hypertension. [13],[14],[15],[16],[17],[18] In addition to numerous cross-sectional analyses, two prospective studies have demonstrated that lower baseline 25(OH)D levels are associated with an increased risk of incident

hypertension. [15],[16] In the first study which included 613 men and 1198 women who did not have hypertension at baseline, those with 25(OH)D levels <15 ng/ml (vitamin D deficiency) compared to those with ≥30 ng/ml had a relative risk for incident hypertension of 2.7 after adjusting for multiple demographic and lifestyle factors. [16] The second prospective study also considered levels of parathyroid hormone plus numerous other biomarkers as potential confounders and found that individuals with vitamin D insufficiency [25(OH)D level < 30 ng/ml] had a 1.5-fold higher risk of developing hypertension compared with those with optimal levels. [15]

In contrast, few human studies have examined this relationship. The first human study to investigate the association examined 10 normotensive individuals as well as 51 hypertensive individuals, on ambient diets, divided into low-renin, normal-renin, and high-renin status. [9] The authors reported the highest levels of 1,25(OH)2D in low-renin hypertensives compared with normal- and high-renin hypertensives (P < 0.01 for both comparisons) as well as normotensives (P < 0.01). Among all 61 individuals, there was an inverse correlation between PRA and 1,25(OH)2D (r = −0.65; P < 0.001). [9] The second human study included 10 high-renin hypertensive individuals who were studied initially on a 5-day low-sodium diet (10 mmol/d) and then again after a 5-day high-sodium diet (100 mmol/d). [19] The authors found that changing from a low-sodium to high-sodium diet led to significant increases in urine calcium excretion and 1,25(OH)2D levels, plus a decrease in PRA. The changes in 1,25(OH)2D concentration and PRA were inversely correlated (r = −0.76; P < 0.01). [19] The authors hypothesized that sodium loading led to an increase in calcium excretion, which in turn led to an increase in 1,25(OH)2D levels, which then suppressed PRA by increasing juxtaglomerular cell calcium concentrations. [19] Levels of 25(OH)D were not measured in either of these studies.

One randomized trial of vitamin D supplementation (with ergocalciferol) documented the effects on markers of the RAS. [20] Sugden et al.[20] randomized 34 individuals with type 2 diabetes mellitus and 25(OH)D levels <20 ng/ml to receive either 100,000 IU of vitamin D2 or placebo. Along with a 6-ng/ml increase in 25(OH)D level at 8 weeks of follow-up with supplementation, SBP declined by 14 mm Hg compared with placebo. In addition, Ang II levels decreased by 13.1 pg/ml in the vitamin D group relative to the change in the placebo group; conversely, active renin levels (not PRA) were increased in the vitamin D group relative to the change in the placebo group by 2.6 ng/ml. [20] Neither of these results was statistically significant. Though we did not take into consideration the sodium and calcium intake by our patients, we noticed significantly higher blood pressure among patients with lower serum 25(OH)D levels in our study.

Another study found out that among 184 normotensive individuals in high sodium balance, lower plasma 25(OH)D levels were associated with significantly higher circulating Ang II concentrations, as well as a blunted Renal plasma flow (RPF) response to infused Ang II. [21] In contrast, although PRA was higher among individuals with vitamin D insufficiency and deficiency, the association was not statistically significant. These findings may reflect a renin-independent mechanism for vitamin D suppression of systemic and local Ang II. Indeed, vitamin D signaling may inhibit the expression of angiotensinogen by inhibition of nuclear factor κB transcription factors[22],[23] and angiotensinogen may be converted by cathepsins to Ang II in the absence of renin. [24],[25] All the patients in our study group were hypertensives; we did not take normotensive subjects into consideration. In our study population, PRA was higher in subjects with vitamin D insufficiency, reflecting a renin-mediated mechanism for hypertension.

We found that lower serum 25(OH)D levels were associated with higher SBP, DBP, MAP and PRA and PAC. Several putative mechanisms have been proposed, including associations between vitamin D deficiency and endothelial dysfunction, [20],[26],[27],[28] inflammation, [29],[30],[31] and insulin resistance. [32],[33] However, a major proposed mechanism was documented by Li et al.[34] in mice lacking the VDR gene. Absence of vitamin D signaling in these animals led to an increase in renin gene expression and circulating Ang II levels. When placed on a high-salt diet, these knockout mice had slight reductions of renin and Ang II, but maintained the levels substantially higher than those of wild-type mice on a similar diet. [35] Furthermore, renin levels remained elevated despite normalization of plasma calcium concentrations, and injection of 1,25(OH)2D reduced renin expression in wild-type mice. [34],[35] Other animal models support these findings, demonstrating that mice lacking the 1α-hydroxylase gene have a similar phenotype[4] and that 1,25(OH)2D analogs help suppress Ang II-mediated kidney injury in diabetic and in 5/6 nephrectomized rats. [36],[37] 25(OH)D deficiency could explain the augmented adipose tissue RAAS activity and the resultant changes in adiponectin concentrations in obesity.

Obesity is a state of hypoadiponectinemia and relative vitamin D deficiency. Vaidya et al. reported in their study that on comparison of patients with low sodium intake and those with high sodium intake, the latter ones had significantly higher SBP, DBP, MAP, PRA, PAC, and adiponectin levels. Adiponectin was found to be inversely associated with BMI and positively associated with 25(OH)D regardless of dietary sodium intake and circulating RAAS activity, [38] which are known modulators of circulating adiponectin. [39],[40] The association between 25(OH)D and adiponectin strengthened with increasing BMI and was only significant among obese individuals where the burden of adipose tissue RAAS activity is expected to be higher. They speculated that adipose tissue RAAS is an important negative paracrine regulator of adiponectin secretion in adipose tissue; [41] the adipose tissue RAAS may in turn be negatively regulated by vitamin D. [9],[10] The adipose tissue RAAS is not influenced by the traditional sodium homeostasis and blood pressure feedback mechanisms, [42] and has been shown to modulate adiponectin concentrations in transgenic mice. [41] With this hypothesized mechanism, vitamin D supplementation could raise circulating adiponectin in obesity by downregulating adipose tissue RAAS activity. [43] The findings of insignificantly higher blood parameters in our study population might be reflective of the mixture of high and low sodium intake by the patients. Though PRA and PAC values were significantly higher in overweight versus lean subjects (P = 0.001), they did not significantly differ according to BMI status in obese versus overweight subjects (P = 0.1) in our study. Higher BMI leads to renin-mediated hypertension; the small sample size of our study population might have been a limitation, as the significance of this association was not found in obese subjects. The significantly lower level of 25(OH)D might have led to increased PRA in overweight subjects in our study population.

Our study examined plasma 25(OH)D levels; the aforementioned animal and previous human investigations of vitamin D and the RAS, in contrast, have mostly focused on levels of 1,25(OH)2D. Because plasma 25(OH)D is not under homeostatic control, whereas 1,25(OH)2D levels are homeostatically regulated, individuals with low 25(OH)D levels may have normal levels of 1,25(OH)2D; however, the two hormones are generally well correlated. [44] In addition, and more importantly, the epidemiological data supporting a relation between vitamin D and hypertension, as well as between vitamin D and cardiovascular disease, are essentially limited to the analyses of 25(OH)D and not 1,25(OH)2D. Therefore, to invoke the RAS as a mechanism to explain the epidemiological data, it was critical to analyze the levels of 25(OH)D.

Finally, several lines of evidence suggest that 25(OH)D, like 1,25(OH)2D, may be an "active" hormone. The 1α-hydroxylase gene is widely expressed.[45] So, 25(OH)D may be converted to 1,25(OH)2D locally in various tissues, bypassing the need for conversion in the proximal tubule and thereby having autocrine and paracrine effects. Furthermore, depending on the conformation of the VDR (cis or trans), it may be located either in the cytoplasm or at the plasma membrane, the latter localization associated with its ability to activate second messengers, such as protein kinase-C, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. [46] New data suggest that whereas the affinity of cytoplasmic VDR is greatest for 1,25(OH)2D, the binding affinity of 25(OH)D for membrane-associated VDR matches that of 1,25(OH)2D. [47] Considering that 25(OH)D concentrations are 1000-fold higher than those of 1,25(OH)2D, it is increasingly apparent that 25(OH)D may be an important active circulating hormone.

The limitations of our study were the following:

  1. This study had a small sample size from a single center with no inclusion of normotensive subjects.
  2. We did not measure plasma levels of parathyroid hormone or 1,25(OH)2D, and therefore cannot examine whether these hormones mediate or confound our observed association.
  3. We did not gather dietary information on calcium and sodium intake and did not know whether the participants were using vitamin D supplements.
  4. We lacked information about sodium and calcium intake.
  5. We did not take into account the time of the year and seasonality which are known to influence 25(OH)D levels. [48] We also did not observe the effect of vitamin D supplementation and weight reduction on these parameters.
  6. We did not have any information on patients taking nonsteroidal anti-inflammatory drugs (NSAID). Because renal prostaglandins may regulate the 1α-hydroxylase enzyme and thus influence the conversion of 25(OH)D to 1,25(OH)D.[45] , NSAIDs by virtue of their inhibitory effect on prostaglandin production might lead to alteration in vitamin D levels.

Nevertheless, given the high prevalence of vitamin D deficiency [49] and ever rising trends in obesity in India, we feel that our study is an important one in supporting the hypothesis of higher incidence of hypertension in vitamin D deficient and obese individuals. Further large-scale, multicenter studies involving larger number of patients with a long follow-up after vitamin D supplementation would serve the purpose of confirming the observations of our preliminary study.

   Conclusion Top

Our findings in newly detected hypertensive individuals show an association between low plasma 25(OH)D levels, high BMI and upregulation of the RAAS. These findings may partly explain the higher risk of developing hypertension observed among individuals with vitamin D insufficiency and deficiency and obesity. Randomized trials should be performed to confirm or refute these observations.

   Acknowledgements Top

The authors extend their heartfelt thanks to Dr. Jagadeesh Tangudu, M Tech, MS, PhD, and Sowmya Jammula, M Tech for their immense and selfless contribution toward manuscript preparation, language editing and final approval of text.

   References Top

1.Beydoun MA, Boueiz A, Shroff MR, Beydoun HA, Wang Y, Zonderman AB. Associations amonmg 25-Hydroxyvitamin D, Diet quality and metabolic disturbance differ by adiposity in United State Adults. J Clin Endocrinol Metab 2010;95:814-27.  Back to cited text no. 1
2.Luft F. The Renin, Angiotensin, Aldosterone and Obesity connection. J Mol Med 2010;88:861-4.  Back to cited text no. 2
3.Yvan-Charvet L, Quignard-Boulange A. Role of adipose tissue rennin-angiotensin system in metabolic and ingflammatory diseases associated with obesity. Kidney Int 2010;79:162-8.   Back to cited text no. 3
4.Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium independent and 1,25(OH)2(D)3-dependent regulation of the rennin-angiotensin system in 1 a hydroxylase knock out mice. Kidney Int 2008;73:163-71.  Back to cited text no. 4
5.Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Investig 2002;110:229-38.  Back to cited text no. 5
6.Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008;74:170-9.  Back to cited text no. 6
7.Kong J, Qiao G, Zhang Z. Liu SQ, Li YC. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses rennin expression independent of parathyroid hormone and calcium. Kidney Int 2008;74:1577-81.  Back to cited text no. 7
8.Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Chem Biol 2007;282:29821-30.  Back to cited text no. 8
9.Resnick LM, Muller Fb, Laragh JH. Calcium regulating hormones in essential hypertension. Relation to plasma rennin activity and sodium metabolism. Ann Intern Med 1986;105:649-54.  Back to cited text no. 9
10.Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, et al. Independent association between 1, 25 dihydroxyvitamin D and the rennin-angiotensin system. The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Clin Chim Acta 2010;411:17-8.  Back to cited text no. 10
11.Dluhy RG, Williams GH. Aldosterone-villain or bystander? N Engl J Med 2004;351:8-10.  Back to cited text no. 11
12.Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.  Back to cited text no. 12
13.Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003;16:72-5.  Back to cited text no. 13
14.Duprez D, de Buyzere M, de Backer T, Clement D. Relationship between vitamin D3 and the peripheral circulation in moderate arterial primary hypertension. Blood Press 1994;3:389-93.  Back to cited text no. 14
15.Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008;52:828-32.  Back to cited text no. 15
16.Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49:1063-9.  Back to cited text no. 16
17.Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: The Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008;57:2619-25.  Back to cited text no. 17
18.Gannage-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol 2009;160:965-71.  Back to cited text no. 18
19.Burgess ED, Hawkins RG, Watanabe M. Interaction of 1,25- dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens 1990;3:903-5.  Back to cited text no. 19
20.Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008;25:320-5.  Back to cited text no. 20
21.Forman JP, Williams JS, Fisher ND. Plasma 25-Hydroxyvitamin D and Regulation of the Renin- Angiotensin System in Humans. Hypertension 2010;55:1283-8.  Back to cited text no. 21
22.Deb DK, Chen Y, Zhang Z, Zhang Y, Szeto FL, Wong KE, et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am J Physiol Renal Physiol 2009;296:F1212-8.  Back to cited text no. 22
23.Li J, Brasier AR. Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcription factor: One mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol 1996;10:252-64.  Back to cited text no. 23
24.Graciano ML, Cavaglieri Rde C, Delle H, Dominguez WV, Casarini DE, Malheiros DM, et al. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 2004;15:1805-15.  Back to cited text no. 24
25.Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83:3925-9.  Back to cited text no. 25
26.Kahonen M, Nappi S, Jolma P, Hutri-Kahonen N, Tolvanen JP, Saha H, et al. Vascular influences of calcium supplementation and vitamin D-induced hypercalcemia in NaCl hypertensive rats. J Cardiovasc Pharmacol 2003;42:319-28.  Back to cited text no. 26
27.London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, et al. Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007;18:613-20.  Back to cited text no. 27
28.Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008;295:H289-96.  Back to cited text no. 28
29.Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: Direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995;15:5789-99.  Back to cited text no. 29
30.D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3: Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998;101:252-62.  Back to cited text no. 30
31.van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. J Steroid Biochem Mol Biol 2005;97:93-101.  Back to cited text no. 31
32.Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005;28:1228-30.  Back to cited text no. 32
33.Reis JP, von Muhlen D, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007;30:1549-55.  Back to cited text no. 33
34.D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-38.  Back to cited text no. 34
35.Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004;89-90:387-92.  Back to cited text no. 35
36.Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796-806.  Back to cited text no. 36
37.Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008;73:163-71.  Back to cited text no. 37
38.Vaidya A, Forman JP, Underwood PC, Hopkins PN, Williams GH, Pojoga LH, et al. Th e influence of Body Mass Index and Renin- Angiotensin-Aldostterone System Activity on the Relationship between 25-Hydroxyvitamin D and Adiponectin in Caucasian Men. Eur J Endocrinol 2011;164:995-1002.  Back to cited text no. 38
39.Krikken JA, Dallinga-Thie GM, Navis G, Dullaart RP. Short term dietary sodium restriction decreases HDL cholesterol, apolipoprotein A-I and high molecular weight adiponectin in healthy young men: Relationships with renal hemodynamics and RAAS activation. Nutr Metab Cardiovasc Dis 2010. [In Press].  Back to cited text no. 39
40.Lely AT, Krikken JA, Bakker SJ, Boomsma F, Dullaart RP, Wolffenbuttel BH, et al. Low dietary sodium and exogenous angiotensin II infusion decrease plasma adiponectin concentrations in healthy men. J Clin Endocrinol Metab 2007;92:1821-6.  Back to cited text no. 40
41.Kim S, Soltani-Bejnood M, Quignard-Boulange A, Massiera F, Teboul M, Ailhaud G, et al. The Adipose Renin-Angiotensin System Modulates Systemic markers of Insulin Sensitivity and Activates Intrarenal Renin-Angiotensin System. J Biomed Biotechnol 2006;2006:27012.  Back to cited text no. 41
42.Engeli S, Boschmann M, Frings P, Beck L, Janke J, Titze J, et al. Influence of Salt Intake on Renin-Angiotensin and Natriuretic Peptide System Genes in Human Adipose Tissue. Hypertension 2006;48:1103-8.  Back to cited text no. 42
43.Vaidya A, Forman JP. Vitamin D and Hypertension: Current evidence and future directions. Hypertension 2010;56:774-9.  Back to cited text no. 43
44.Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:1340-9.  Back to cited text no. 44
45.Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.   Back to cited text no. 45
46.Norman AW. Minireview: Vitamin D receptor-new assignments for an already busy receptor. Endocrinology 2006;147:5542-8.  Back to cited text no. 46
47.Mizwicki MT, Norman AW. The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapidresponse signaling. Sci Signal 2009;2:re4.  Back to cited text no. 47
48.Wark JD, Larkins RG, Eisman JA, Wilson KR. Regulation of 25-hydroxy-vitamin D-1 a-hydroxylase in chick isolated renal tubules: Effects of prostaglandin E2, frusemide and acetylsalicylic acid. Clin Sci (Lond) 1981;61:53-9.  Back to cited text no. 48
49.Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporosis Int 2009;20:1807-20.  Back to cited text no. 49


  [Figure 1], [Figure 2]

  [Table 1], [Table 2]

This article has been cited by
1 Vitamin D deficiency and co-morbidities in COVID-19 patients – A fatal relationship?
Hans K. Biesalski
NFS Journal. 2020; 20: 10
[Pubmed] | [DOI]
2 Vitamin D status of overweight and obese Bangladeshi adults
AjitK Paul,AB M Kamrul-Hasan,PalashK Chanda,DulalC Nandi
Journal of Family Medicine and Primary Care. 2020; 9(7): 3444
[Pubmed] | [DOI]
3 Hypovitaminosis D and Cardiometabolic Risk Factors in Adolescents with Severe Obesity
Teodoro Durá-Travé,Fidel Gallinas-Victoriano,Diego Mauricio Peñafiel-Freire,María Urretavizcaya-Martinez,Paula Moreno-González,María Jesús Chueca-Guindulain
Children. 2020; 7(2): 10
[Pubmed] | [DOI]
4 Association of serum 25-hydroxyvitamin D levels with primary hypertension: a study from south India
Pramod Kumar Kuchulakanti,Jaydip Ray Chaudhuri,Urmila Annad,Naveen Reddy Samala,Lakshumaiah Tallapaneni,Banda Balaraju,VCS Srinivasarao Bandaru
Hypertension Research. 2020;
[Pubmed] | [DOI]
5 Vitamin D and Cardio-Metabolic Risk Factors in Overweight Adults: An Overview of the Evidence
Ana Valer-Martinez,J. Alfredo Martinez,Carmen Sayon-Orea,Fabio Galvano,Giuseppe Grosso,Maira Bes-Rastrollo
Current Pharmaceutical Design. 2019; 25(22): 2407
[Pubmed] | [DOI]
6 Vitamin D in inflammation mitigation and role as signaling molecule
Seema Patel
Gene Reports. 2018; 12: 74
[Pubmed] | [DOI]
7 Implications of vitamin D toxicity & deficiency
Susan Waterbury
The Nurse Practitioner. 2018; 43(5): 22
[Pubmed] | [DOI]
8 The Antioxidant Therapy: New Insights in the Treatment of Hypertension
Daniela Sorriento,Nicola De Luca,Bruno Trimarco,Guido Iaccarino
Frontiers in Physiology. 2018; 9
[Pubmed] | [DOI]
9 The Relationship between Vitamin D and Coronary Artery Ectasia in Subjects with a Normal C-Reactive Protein Level
Goksel Cagirci,Selcuk Kucukseymen,Isa Oner Yuksel,Nermin Bayar,Erkan Koklu,Ramazan Guven,Sakir Arslan
Korean Circulation Journal. 2017; 47(2): 231
[Pubmed] | [DOI]
10 Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies
Seema Patel,Abdur Rauf,Haroon Khan,Tareq Abu-Izneid
Biomedicine & Pharmacotherapy. 2017; 94: 317
[Pubmed] | [DOI]
11 Both high and low plasma levels of 25-hydroxy vitamin D increase blood pressure in a normal rat model
Naghmeh Z. Mirhosseini,Steven J. Knaus,Kaylee Bohaychuk,Jaswant Singh,Hassan A. Vatanparast,Lynn P. Weber
British Journal of Nutrition. 2016; 116(11): 1889
[Pubmed] | [DOI]
12 Low vitamin D is associated with hypertension in paediatric obesity
Kung-Ting Kao,Nobia Abidi,Sanjeeva Ranasinha,Justin Brown,Christine Rodda,Zoe McCallum,Margaret Zacharin,Peter J Simm,Costan G Magnussen,Matthew A Sabin
Journal of Paediatrics and Child Health. 2015; 51(12): 1207
[Pubmed] | [DOI]
13 Interplay of vitamin D and metabolic syndrome: A review
Priyanka Prasad,Anita Kochhar
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2015;
[Pubmed] | [DOI]
14 Vitamin D and nifedipine in the treatment of Chinese patients with grades I–II essential hypertension: A randomized placebo-controlled trial
Wei Ren Chen,Zhi Ying Liu,Yang Shi,Da Wei Yin,Hao Wang,Yuan Sha,Yun Dai Chen
Atherosclerosis. 2014; 235(1): 102
[Pubmed] | [DOI]
15 Amlodipine Increases Vitamin D Levels More Than Valsartan in Newly Diagnosed Hypertensive Patients: Pointing to an Additional Effect on Bone Metabolism or a Novel Marker of Inflammation?
Seyit Ahmet Ay,Murat Karaman,Mustafa Cakar,Sevket Balta,Erol Arslan,Fatih Bulucu,Seref Demirbas,Turgay Celik,Mehmet Ilkin Naharci,Sait Demirkol,Omer Kurt,Ergun Bozoglu
Renal Failure. 2013; 35(5): 691
[Pubmed] | [DOI]
16 The beneficial role of vitamin D in obesity: possible genetic and cell signaling mechanisms
Khanh vinh qu?c Luong,Lan Thi Hoàng Nguy?n
Nutrition Journal. 2013; 12(1)
[Pubmed] | [DOI]
17 Relation of Low Vitamin D to Nonvalvular Persistent Atrial Fibrillation in Chinese Patients
Wei Ren Chen,Zhi Ying Liu,Yang Shi,Da Wei Yin,Hao Wang,Yuan Sha,Yun Dai Chen
Annals of Noninvasive Electrocardiology. 2013; : n/a
[Pubmed] | [DOI]
18 The Effects of Low Vitamin D on Coronary Artery Disease
Wei Ren Chen,Yong An Qian,Yun Dai Chen,Yang Shi,Da Wei Yin,Hao Wang,Ping Zhu,Hong Wei Liu,Yuan Sha
Heart, Lung and Circulation. 2013;
[Pubmed] | [DOI]
19 Concentrações de 25-hidroxivitamina D e níveis pressóricos em idosos hipertensos
Juliana Padilha Ramos Neves,Alexandre Sérgio Silva,Liana Clébia Soares Lima de Morais,Alcides da Silva Diniz,Maria José de Carvalho Costa,Luiza Sonia Rios Asciutti,Maria da Conceição Rodrigues Gonçalves
Arquivos Brasileiros de Endocrinologia & Metabologia. 2012; 56(7): 415
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Materials and Me...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded626    
    Comments [Add]    
    Cited by others 19    

Recommend this journal